miR-134: A Human Cancer Suppressor?
MicroRNAs (miRNAs) are small noncoding RNAs approximately 20-25 nt in length, which play crucial roles through directly binding to corresponding 3' UTR of targeted mRNAs. It has been reported that miRNAs are involved in numerous of diseases, including cancers. Recently, miR-134 has been identified to dysregulate in handles of human cancers, such as lung cancer, glioma, breast cancer, colorectal cancer, and so on. Increasing evidence indicates that miR-134 is essential for human carcinoma and participates in tumor cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. Nevertheless, its roles in human cancer are still ambiguous, and its mechanisms are sophisticated as well, referring to a variety of targets and signal pathways, such as STAT5B, KRAS, MAPK/ERK signal pathway, Notch pathway, etc. Herein, we review the crucial roles of miR-134 in scores of human cancers via analyzing latest investigations, which might provide evidence for cancer diagnose, treatment, prognosis, or further investigations.
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China.
Jing-Yu
JY
Pan
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China.
Feng
F
Zhang
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China. Electronic address: chengcaosun@whu.edu.cn.
Cheng-Cao
CC
Sun
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China; Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, 430015 Wuhan, Hubei, P. R. China.
Shu-Jun
SJ
Li
Department of Oncology, Wuhan Pu-Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430034 Wuhan, Hubei, P. R. China.
Guang
G
Li
Department of Infectious Diseases, Wuhan Medical Treatment Center, 430023 Wuhan, Hubei, P. R. China.
Feng-Yun
FY
Gong
Department of Infectious Diseases, Wuhan Medical Treatment Center, 430023 Wuhan, Hubei, P. R. China.
Tao
T
Bo
Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 510623 Guangzhou, Guangdong, P. R. China.
Jing
J
He
Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, P. R. China.
Rui-Xi
RX
Hua
Department of Oncology, ZhongNan Hospital of Wuhan University, 430071 Wuhan, Hubei, P. R. China.
Wei-Dong
WD
Hu
Department of Toxicology, School of Public Health, Wuhan University, 430071 Wuhan, P. R. China.
Zhan-Peng
ZP
Yuan
Department of Social Science and Public Health, School of Basic Medical Science, Jiujiang University, Jiujiang 332000, China.
Xin
X
Wang
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China.
Qi-Qiang
QQ
He
Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China. Electronic address: lodjlwhu@sina.com.
De-Jia
DJ
Li
human cancer; miR-134; microRNA